Predicting Axillary Response in Hormone Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy Using Real-World Data
Table 2
Univariate analysis of axillary in patients from the test set (n = 175).
Characteristics
OR
95% Cl
values
Age
0.990
0.956–1.027
0.602
Clinical T stage
1
REF
2
0.552
0.174–1.751
0.313
3
1.818
0.300–11.023
0.516
4
0.818
0.179–3.739
0.796
Clinical N stage
1
REF
2
2.723
1.096–6.762
0.031
3
4.566
1.007–20.714
0.049
US of lymph nodes
Negative
REF
Positive
4.102
17.47–9.631
0.001
Histologic type
IDC
REF
Other
0.570
0.123–2.649
0.473
NAC regimes
A
REF
T
0.455
0.084–2.469
0.361
A + T
1.131
0.418–3.062
0.808
NAC cycles
<4
REF
4–6
0.553
0.063–4.844
0.593
<6
0.769
0.085–6.944
0.815
Breast surgery
BCS
4.992
1.833–13.598
0.002
Mastectomy
REF
ypT stage
0
REF
1–4
1.806
0.523–6.237
0.350
Histologic grade
I/II
REF
III
2.211
0.828–5.904
0.113
Ki-67
<14
3.346
1.544–7.252
0.002
≥14
REF
HER2
Negative
2.367
1.011–5.538
0.047
positive
REF
LVI
Negative
REF
Positive
3.634
1.329–9.937
0.012
OR = odds ratio; CI = confidence interval; REF = reference; HER2 = human epidermal growth factor receptor 2; LVI = lymphovascular invasion. Only patients with available data were used in the analysis.